amiodarone has been researched along with metformin in 19 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 5 (26.32) | 29.6817 |
2010's | 12 (63.16) | 24.3611 |
2020's | 2 (10.53) | 2.80 |
Authors | Studies |
---|---|
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
Lombardo, F; Obach, RS; Waters, NJ | 1 |
Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM | 1 |
Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
Glen, RC; Lowe, R; Mitchell, JB | 1 |
Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ | 1 |
Ekins, S; Williams, AJ; Xu, JJ | 1 |
Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Miao, GX; Wang, YD; Yan, ZW; Zhang, LY | 1 |
Dolovcak, S; Emmett, D; Esser, V; Fitz, JG; Kilic, G; Parameswara, V; Puljak, L; Waldrop, SL | 1 |
Fey, SJ; Wrzesinski, K | 1 |
Kalamida, D; Koukourakis, MI; Mitrakas, AG | 1 |
Gilowska, M; Krysiak, R; Okopień, B; Szkróbka, W | 1 |
Hosomi, K; Kinoshita, S; Takada, M; Yokoyama, S | 1 |
1 review(s) available for amiodarone and metformin
Article | Year |
---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
18 other study(ies) available for amiodarone and metformin
Article | Year |
---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Topics: | 2008 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
Predicting phospholipidosis using machine learning.
Topics: Animals; Artificial Intelligence; Databases, Factual; Drug Discovery; Humans; Lipidoses; Models, Biological; Phospholipids; Support Vector Machine | 2010 |
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Synthesis, in vitro ADME profiling and in vivo pharmacological evaluation of novel glycogen phosphorylase inhibitors.
Topics: Animals; Blood Glucose; Cell Proliferation; Diabetes Mellitus, Experimental; Dose-Response Relationship, Drug; Enzyme Inhibitors; Epinephrine; Glycogen Phosphorylase; Hep G2 Cells; Hepatocytes; Humans; Hypoglycemic Agents; Indoles; Mice; Molecular Structure; Rats; Structure-Activity Relationship | 2020 |
Evidence for AMPK-dependent regulation of exocytosis of lipoproteins in a model liver cell line.
Topics: Aminoimidazole Carboxamide; Amiodarone; AMP-Activated Protein Kinases; Animals; Apolipoproteins B; Cell Line; Enzyme Inhibitors; Epoxy Compounds; Exocytosis; Fatty Acids; Hepatocytes; Humans; Hypoglycemic Agents; Lipid Metabolism; Lovastatin; Metformin; Multienzyme Complexes; Oxidation-Reduction; Patch-Clamp Techniques; Protein Serine-Threonine Kinases; Rats; Ribonucleotides; Sterol Regulatory Element Binding Protein 1; Triglycerides | 2008 |
Determination of drug toxicity using 3D spheroids constructed from an immortal human hepatocyte cell line.
Topics: Acetaminophen; Adenosine Triphosphate; Amiodarone; Bioreactors; Diclofenac; Dose-Response Relationship, Drug; Hep G2 Cells; Hepatocytes; Humans; Lethal Dose 50; Metformin; Phenformin; Proteins; Reproducibility of Results; Risk Assessment; Spheroids, Cellular; Toxicity Tests; Valproic Acid | 2012 |
Effect of mitochondrial metabolism-interfering agents on cancer cell mitochondrial function and radio/chemosensitivity.
Topics: Amiodarone; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Cisplatin; Docetaxel; Drug Resistance, Neoplasm; Drug Synergism; Humans; Lung Neoplasms; Male; Metformin; Mitochondria; Prostatic Neoplasms; Radiation Tolerance; Taxoids | 2014 |
The effect of metformin on the hypothalamic-pituitary-thyroid axis in patients with type 2 diabetes and amiodarone-induced hypothyroidism.
Topics: Aged; Amiodarone; Diabetes Mellitus, Type 2; Female; Humans; Hypothalamo-Hypophyseal System; Hypothyroidism; Insulin; Insulin Resistance; Insulin-Like Growth Factor I; Male; Metformin; Middle Aged; Prolactin; Thyroid Gland; Thyrotropin; Thyrotropin-Releasing Hormone; Thyroxine | 2016 |
Inverse Association between Metformin and Amiodarone-Associated Extracardiac Adverse Events.
Topics: Adverse Drug Reaction Reporting Systems; Amiodarone; Humans; Hyperthyroidism; Hypoglycemic Agents; Lung Diseases, Interstitial; Metformin; Odds Ratio; Retrospective Studies | 2020 |